Citi: CSL Injectafer black box label warning likely limited impact
Citi says the FDA-approved revised Injectafer labeling—adding a black box warning about low blood phosphate risk—is unlikely to change much for CSL.
The addition of a black box warning to the label of CSL's Injectafer is unlikely to have a big impact, according to Citi.
The Food and Drug Administration approved revised labeling for the iron replacement medicine to warn of the risk of low levels of phosphate in the blood. "We do not think it wil…